WO2026105071 - ANTI-THYMIC STROMAL LYMPHOPOIETIN (TSLP) MONOCLONAL ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS
National phase entry is expected:
Publication Number
WO/2026/105071
Publication Date
21.05.2026
International Application No.
PCT/IB2025/061679
International Filing Date
15.11.2025
Title **
[English]
ANTI-THYMIC STROMAL LYMPHOPOIETIN (TSLP) MONOCLONAL ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS
[French]
ANTICORPS MONOCLONAUX ANTI-LYMPHOPOÏÉTINE STROMALE THYMIQUE (TSLP) ET MÉTHODES DE TRAITEMENT DE LA DERMATITE ATOPIQUE
Applicants **
BIOSION INC.
Inventors
CHEN, Mingjiu
DAVIS, Hugh Michael
Priority Data
63/721,235
15.11.2024
US
63/869,888
25.08.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2676 | |
| EPO | Filing, Examination, Granting | 12420 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2413 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,556
Contact Us
Abstract[English]
The present disclosure relates to monoclonal antibodies that specifically bind to thymic stromal lymphopoietin (TSLP) and methods for treating atopic dermatitis. The antibodies block TSLP interaction with its receptor complex, preventing downstream inflammatory signaling. Administration involves weekly loading doses followed by biweekly maintenance doses, achieving superior clinical efficacy with >90% reduction in disease severity. The antibodies demonstrate favorable pharmacokinetics with a 25-day half-life, low immunogenicity, and a well-tolerated safety profile. This disclosure also covers methods for evaluating treatment efficacy and safety in moderate to severe atopic dermatitis patients.[French]
La présente divulgation concerne des anticorps monoclonaux qui se lient de manière spécifique à la lymphopoïétine stromale thymique (TSLP) et des méthodes de traitement de la dermatite atopique. L'anticorps bloque l'interaction TSLP avec son complexe récepteur, empêchant une signalisation inflammatoire en aval. L'administration implique le chargement hebdomadaire de doses suivies par des doses d'entretien bihebdomadaire, ce qui permet d'obtenir une efficacité clinique supérieure avec > 90% de réduction de la gravité de la maladie. Les anticorps démontrent une pharmacocinétique favorable avec une demi-vie de 25 jours, une faible immunogénicité et un profil de sécurité bien toléré. La présente divulgation concerne également des procédés d'évaluation de l'efficacité de traitement et de la sécurité chez des patients atteints de dermatite atopique modérée à grave.